Conditions: Chronic Plaque Psoriasis
Keywords: chronic plaque psoriasis, anti TNFα CDP870, Cimzia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 176
Healthy volunteers: no

Brief summary:
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.

Detailed description:

Arms:
arm 1: Subcutaneous injections of Placebo every 2 weeks arm 2: Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter arm 3: Subcutaneous injections of 400 mg every 2 weeks

Interventions: intervention 1: Certolizumab Pegol intervention 2: Placebo
Intervention descriptions: intervention 1: * Pharmaceutical Form: solution for injection in pre-filled syringe
* Route of Administration: subcutaneous use intervention 2: Matching Placebo to Certolizumab Pegol

Protocol document: